medigraphic.com

2019, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2019; 57 (2)

Cytokines and nervous system: relationship with schizophrenia

Ramírez-Jirano LJ, Velasco-Ramírez SF, Pérez-Carranza GA, Domínguez-Díaz C, Bitzer-Quintero OK

Language: Spanish
References: 29
Page: 107-112
PDF size: 128.92 Kb.


ABSTRACT

Schizophrenia is a heterogeneous disorder of mental symptoms and alterations, characterized by presenting abnormal ideas and perceptions, in which the individual loses contact with reality as a result of a complex neuropsychological disorganization, which affects the affective, intellectual and behavioral functioning; as well as inducing a significant social dysfunction.
The etiology of schizophrenia is extremely complex, and is not very clear yet; it is believed to be the result of the combination of genetic factors and the environment.
Numerous neurotransmitters have been implicated in this disease, as is the case of dopamine, serotonin and glutamate.
The role of the inflammatory process in the pathogenesis of schizophrenia has been postulated, where a prenatal immune "challenge" during the second trimester of pregnancy can be key to the development of the disease.
Some of the pro-inflammatory cytokines (TNF-alpha, IL- 1beta and IL-6) play a key role in the processes of modulation of the nervous system functions related to affective, emotional and social alterations in subjects with schizophrenia.
The mechanisms associated with inflammation and the anti-inflammatory defense system that may be associated with the development of schizophrenia are still unknown.
This review was intended to address schizophrenia, in regards to the mechanisms associated with inflammation and the anti-inflammatory defense system in its development.


REFERENCES

  1. Ferrero-Rodríguez LM, Pérez-Magín IM, Gómez-Padrón EI, Loynaz-Fernández CS, Rodríguez-Rodríguez A. Algunas características anatómicas del encéfalo del esquizofrénico. Rev Cubana Invest Biomed. 2004;23(3): 163-8.

  2. Onstad S, Skre I, Torgersen S, Kringlen E. Twin concordance for DSM-III-R schizophrenia. Acta Psychiatr Scand. 1991;83(5):395-401.

  3. Solter V, Thaller V, Bagarić A, Karlović D, Crnković D, Potkonjak J. Estudio de la esquizofrenia comórbida con la adicción alcohólica. Eur J Psychiat. 2004;18(1):14-22.

  4. Hoff AL, Kremen WS. Neuropsychology in schizophrenia: an update. Current Opinion in Psychiatry. 2003;16(2): 149-55.

  5. Kaymaz N, van Os J. Murray et al. (2004) revisited: is bipolar disorder identical to schizophrenia without developmental impairment? Acta Psychiatr Scand. 2009; 120(4):249-52. DOI: https://doi.org/10.1111/j.1600-0447.2009.01472.x

  6. Dean L. Schizophrenia. En: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A et al. Eds. Medical Genetics Summaries. Bethesda (MD), USA: National Center for Biotechnology Information; 2012. Última actualización, 6 de febrero de 2017. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK62008/

  7. Jenkins TA. Perinatal complications and schizophrenia: involvement of the immune system. Front Neurosci. 2013; 7:110. DOI: 10.3389/fnins.2013.00110

  8. Brown AS, Patterson PH. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull. 2011;37(2):284-90. DOI: https://doi.org/10.1093/schbul/ sbq146

  9. Alvarez MJ, Roura P, Osés A, Foguet Q, Solà J, Arrufat FX. Prevalence and clinical impact of childhood trauma in patients with severe mental disorders. J Nerv Ment Dis. 2011;199(3):156-61.

  10. O'Tuathaigh CM, Babovic D, O'Sullivan GJ, Clifford JJ, Tighe O, Croke DT, et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience. 2007;147(1):18-27. DOI: https://doi.org/ 10.1016/j.neuroscience.2007.03.051

  11. Takano H. Cognitive Function and Monoamine Neurotransmission in Schizophrenia: Evidence From Positron Emission Tomography Studies. Front Psychiatry. 2018;9:228; 1-8. DOI: https://doi.org/10.3389/fpsyt.2018. 00228

  12. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory role of dopamine: an update. Brain Behav Immun. 2010;24(4):525-8. DOI: https://doi.org/ 10.1016/j.bbi.2009.10.015

  13. Merritt K, McGuire P, Egerton A. Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis. Front Psychiatry. 2013; 4:151. DOI: https://doi.org/10.3389/fpsyt.2013.00151

  14. White R, Krämer-Albers EM. Axon-glia interaction and membrane traffic in myelin formation. Front Cell Neurosci. 2014;7:284. DOI: https://doi.org/10.3389/fncel.2013. 00284

  15. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15(7):2011-35.

  16. Müller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub. 2013;25(3):292-8.

  17. Ellman LM, Deicken RF, Vinogradov S, Kremen WS, Poole JH, Kern DM, et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res. 2010; 121(1-3):46-54. DOI: https://doi.org/10.1016/j.schres. 2010.05.014

  18. Dickerson DD, Bilkey DK. Aberrant neural synchrony in the maternal immune activation model: using translatable measures to explore targeted interventions. Front Behav Neurosci. 2013;7:217. DOI: https://doi.org/10.3389/ fnbeh.2013.00217

  19. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet. 2005;6:7. DOI: https://doi.org/10.1186/1471-2350-6-7

  20. Barron H, Hafizi S, Andreazza AC, Mizrahi R. Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk. Int J Mol Sci. 2017;18(3). DOI: https://doi.org/10.3390/ijms18030651

  21. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav Immun. 2011;25(8):1507-18. DOI: https:// doi.org/10.1016/j.bbi.2011.05.014

  22. Markham JA, Koenig JI. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl). 2011;214(1):89-106. DOI: https://doi.org/10.1007/s00213- 010-2035-0

  23. Canetta SE, Brown AS. Prenatal Infection, Maternal Immune Activation, and Risk for Schizophrenia. Transl Neurosci. 2012;3(4):320-7. DOI: https://doi.org/10.2478/ s13380-012-0045-6

  24. Schmitz T, Chew LJ. Cytokines and myelination in the central nervous system. TheScientificWorldJOURNAL. 2008;8:1119- 47. DOI: https://doi.org/10.1100/tsw.2008.140

  25. Smyth AM, Lawrie SM. The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci. 2013;11 (3):107-17. DOI: https://doi.org/10.9758/cpn.2013.11.3. 107

  26. Kästner A, Grube S, El-Kordi A, Stepniak B, Friedrichs H, Sargin D, et al. Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. Mol Med. 2012;18:1029-40. DOI: https://doi.org/10.2119/molmed.2012.00190

  27. Roussos P, Haroutunian V. Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities. Front Cell Neurosci. 2014;8:5. DOI: https://doi.org/10.3389/ fncel.2014.00005

  28. Michel M, Schmidt MJ, Mirnics K. Immune system gene dysregulation in autism and schizophrenia. Dev Neurobiol. 2012;72(10):1277-87. Disponible en: https://www.ncbi.nlm. nih.gov/pmc/articles/PMC3435446/

  29. Poon VY, Choi S, Park M. Growth factors in synaptic function. Front Synaptic Neurosci. 2013;5:6. DOI: https:// doi.org/10. 3389/fnsyn.2013.00006




2020     |     www.medigraphic.com